News

Dr. Philip M. Arlen gives scientific presentation at the 4th Annual Europe Neoantigen Summit 20th-22nd April 2021

Strattmont Group2021-04-21T08:30:59-04:00

Dr. Philip M. Arlen gives scientific presentation at the 4th Annual Europe Neoantigen summit, Clinical...

Dr. Philip M. Arlen gives scientific presentation at the Festival of Biologics, World Immunotherapy Congress, USA

Strattmont Group2021-03-26T10:04:55-04:00

Dr. Philip M. Arlen gives scientific presentation at the Festival of Biologics, World Immunotherapy Congress,...

Dr. Philip M. Arlen gives scientific presentation at World Vaccine & Immunotherapy Congress West Coast 2020, December 1 – 3, 2020

Strattmont Group2020-12-01T10:51:12-05:00

Dr. Philip M. Arlen gives scientific presentation at World Vaccine & Immunotherapy Congress West Coast...

Dr. Philip M. Arlen to give scientific presentation at two conferences

Strattmont Group2020-10-16T09:08:06-04:00

Dr. Philip M Arlen, MD, President and CEO is Presenting the Following Talk at the...

Synthetic Antibody Rallies Immune Cells Against Ovarian Cancer

Strattmont Group2020-08-27T09:20:35-04:00

NIH Intramural Research Program (IRP) highlights Precision Biologics NEO-201 monoclonal antibody.

Evaluation of the Anti-Tumor Activity of the Humanized Monoclonal Antibody NEO-201 in Preclinical Models of Ovarian Cancer

Strattmont Group2020-07-15T11:25:40-04:00

Precision Biologics in conjunction with our research collaborators at the National Cancer Institute (NCI) have...

Precision Biologics and the National Cancer Institute deliver 2 Poster Presentations at the AACR virtual meeting June 22-24th, 2020

Strattmont Group2020-06-25T17:47:53-04:00

Precision Biologics along with our collaborators at the National Cancer Institute present research data using...

Results of Precision Biologics Phase 2 Colorectal Cancer Study Published in Clinical Cancer Research

Strattmont Group2020-05-01T12:30:29-04:00

Precision Biologics announces that the results of the Phase II Clinical Trial using its lead...